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quality of life in primary care and identify correlations with demographics and
chronic diseases.
Materials and methods: 500 people (220 men) that visited the Gytheio Health
Center, Greece, participated in the study answering a study questionnaire that
included demographic and somatometric data, medical history, the Zung self-rating
depression scale (SDS-Zung) and the Short Form 12 (SF-12) scale for quality of life eval-
uation with a mental component scale (MCS) and a physical component scale (PCS).
Results: 163 persons (32.6% of the study population) had SDS-Zung scores over 50
indicating depressive symptomatology. Of those 22% of the study population (70%
women) had no awareness of their problem and were under no treatment; 80
(16% of the study population) had mild depressive symptoms (SDS-Zung:
53.12 ± 0.6 [95% CI]) and physical impairment: MCS12: 44.32 ± 1.9 (95% CI), PCS:
39.16 ± 2.2 (95% CI) (p < 0.005) and 23 (4.6% of study population) had moderate
symptoms (SDS-Zung: 63.82 ± 1.34 [95% CI]), with mental and physical impairment:
MCS12: 36.99 ± 1.88 (95% CI), PCS: 34.83 ± 5.12 (95% CI) (p < 0.005) adjusted for age,
sex and co-morbidities. Arthritis and COPD were associated with depressive symp-
tomatology and physical impairment (p < 0.05) and coronary heart disease and con-
gestive heart failure with physical impairment (p < 0.005). Patients under anti-
depressive medication had significant depressive symptomatology and decreased
quality of life (p < 0.0005).
Conclusion: The prevalence of both depressive symptomatology and impairment
of quality of life is significant and primary care with simple, validated tools can be
the setting for identifying and helping such patients.
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Depression is an affective disorder characterized
by lowering of mood, reduction of energy, and a
decrease in activity. The inability to enjoy any
activity, the lack of interest in anything, a reduc-
tion in concentration, marked tiredness after ef-
fort, disturbed sleep patterns and diminished
appetite are all common symptoms of depression.
A marked reduction of self-esteem and self-
confidence, together with ideas of guilt or worth-
lessness are also often present [1].
According to the World Health Organization
depression is currently the fourth leading cause of
disability in the Western world and is expected to
rank second by 2020. In the United States of America
between 1990 and 2000, the cost of treatment for
depression rose by 31.2% (from $19.8 to $26.08 mil-
lion) and the time absent from work by 50% [2].
The aim of this observational study is to identify
the presence of depression, assess the quality of
life of patients visiting primary care in Greece
and to examine whether depressive symptoms
and impairment of quality of life are associated
with chronic health problems, social environment
and personal status.
2. Materials and methods
The study took place at the Gytheio Health Care
Center (GCC). GCC is a public institution with
approximately 8000 referring population, which
doubles during the summer. Public insurance is
mandatory in Greece. Foreigners or uninsured indi-
viduals (immigrants or unemployed) may visit GCC
or any other public institution, and they are
charged accordingly. People with additional pri-
vate insurance may come to a public institution,
but only their public insurance will be charged.
500 consecutive persons that visited GCC on a reg-
ular basis filled out the study questionnaires after
being formally informed and consenting to partici-
pate. When needed, the medical staff of GCC as-
sisted the participants and helped to clarify any
questions. The mean time needed to complete
the questionnaire was 10–20 min.
Participants visited GCC after attending an
appointment for evaluation of a chronic illness, for
reexamination after an acute health problem that
had led them previously to GCC, for laboratory
tests, or for monthly prescription refills. People
were considered eligible for participating in the
study if they were 18 years old, spoke and read
Greek fluently and were both capable and willing
to fill out the questionnaires. People that visitedGCC for an emergency health problem or did not ful-
fill the above criteria were not asked to participate.
The study questionnaire consisted of three
parts. The first included demographic and somato-
metric data of the participant together with infor-
mation from his/her medical history. The second
part was the Zung self-rating depression scale
(SDS-Zung) [3]. The SDS-Zung is a self-reported,
20-item measure of the symptoms of depression.
Item responses are ranked from 1 to 4, with higher
scores corresponding to more frequent symptoms.
Total scores on the SDS-Zung do not correspond
with a clinical diagnosis of depression, but rather
indicate the level of depressive symptoms that
may be of clinical relevance. It has been estab-
lished as a valid, reliable instrument in several
studies in order to measure depressive symptoms
[4–6] and has been translated and validated for
the Greek population [7]. Scores under 50 are con-
sidered normal, scores 50–59 as mild, 60–69 as
moderate and over 70 as severe/extreme depres-
sive symptoms. The third part was the Short
Form-12 (SF-12) scale for the evaluation of
health-associated quality of life. The SF-12 scale
is a condensed version of the SF-36 scale, which
was implemented by the International Quality of
Life Assessment (IQOLA) Project [8] and has since
been translated into more than 60 languages and
validated for the Greek population. The SF-12 is a
shortened version that has proven to be more prac-
tical in large samples when an overall estimate of
physical and mental health is needed [9]. The scale
consists of 12 questions concerning physical func-
tioning and mental and emotional status that form
the physical component summary (PCS) and the
mental component summary (MCS), which are con-
sidered each to consist of 50% of health-associated
quality of life. Scores under 50 indicate impairment
of quality of life physically or mentally accordingly.
Scores under 40 indicate impairment under 1 stan-
dard deviation (SD) from the mean (under 84% of
the population) and scores under 30 under 2 SD (un-
der 98% of the population). The version used was
the one that recalls information of the previous
four weeks [9]. The SF-12 has been used in various
settings and study populations [10,11] and is con-
sidered to be a valid and reliable tool.
The SPSS13 software was used for the statistical
analysis of the results. Normality tests (Kolmogo-
rov–Smirnof and Shapiro–Wilk) showed that the
data did not follow normal distribution, and non-
parametric tests were implemented. Mann–Whit-
ney U-test was used for the comparison of two sub-
groups, and Kruskall Wallis median test for the
comparison of more subgroups. Multiple regression
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whethermultiple chronic illnesses correlate to depres-
sive symptomatology and impaired quality of life.
The study was approved by the ethics commit-
tee of the affiliated hospital (Sparta General Hospi-
tal, Lakonia, Greece) and the National Center of
Health Management.
3. Results
The study population was 500 – 220 men and 280
women. Demographic data of the study population
are shown in Table 1. The largest portion of the
study group was aged 40–90 years (479 persons
[95.6%]); 72.2% were married and 26.4% of the wo-
men were widows; 66% of the sample had lower
education, a percentage that is common in rural
areas of Greece in older age groups; and 52.5% of
the study group were retired. No statistically sig-
nificant differences were found between partici-
pants with different family status, profession and
level of education (p > 0.05).
Chronic illnesses were recorded as shown in Ta-
ble 2. Arterial hypertension was the most common
illness (70% of men and 57.1% of women), followed
by dyslipidemia, diabetes mellitus, osteoarthritis
of large joints and chronic obstructive pulmonary
disease (COPD). A significant number of the study
population (58.6%) reported some kind of chronic
illness, such as renal failure, prostate hypertrophy,
thyroid dysfunction and various malignancies;
7.27% of men and 22.1% of women were taking
anti-depressive medication according to some phy-
sicians (either a GCCs physician or others)
prescription.
Mean scores of the three scales are shown in
Table 3. The scores were adjusted for sex andTable 1 Demographic data.
Age (Mean–St. dev) Men
69.77
Family status (n–% sex–% total)
Single 16 (7
Married 179 (
Divorced 6 (2.7
Widowed 19 (8
Education (n–% sex–% total) Lower 127 (
Intermediate 68 (3
Higher 25 (1
Profession (n–% sex–% total) Retired 151 (
Farmer 32 (1
Household 2 (0.9
Other 35 (1age prompted to a stratified analysis for all co-mor-
bidities. Table 4 summarizes the results adjusted
for sex and age for various co-morbidities. No sta-
tistically significant differences were found in
depressive symptomatology or quality of life in
the subgroup analysis for participants with arterial
hypertension or dyslipidemia. Men with diabetes
mellitus, coronary heart disease and congestive
heart failure had statistically significant different
scores in SDS-Zung and PCS12 scores (p < 0.05),
but not in levels that indicate depression or impair-
ment of quality of life. Participants of both sexes
with chronic arthritis and COPD had marked
depressive symptomatology and impairment of
physical components of quality of life (p < 0.05).
Finally, the results of the subgroup of participants
taking anti-depressive medication (17 men and 62
women) were found to have significant differences
in depressive symptomatology and moderate to se-
vere impairment of quality of life both in the men-
tal and in the physical component of the SF-12
score (p < 0.005 in all subgroups).
The Zung self-rating depression scale indicates
depressive symptomatology when the scores are
over 50. In Tables 5 and 6, the scores of the partic-
ipants that were over 50 in the SDS-Zung are pre-
sented; 163 people had such scores in total. 111
of them were not taking any anti-depressive medi-
cation (22.2% of the study population with a 70%
predominance of women). From them, 80 persons
(16% of the study population) had mild depressive
symptoms (SDS-Zung: 53.12 ± 0.6, MCS12:
44.32 ± 1.9, PCS: 39.16 ± 2.2 [mean ± 2se (95%
CI]). Moderate depressive symptoms were present
in 23 participants (4.6% of the study population).
The depressive symptomatology in both subgroups
is concordant with significant impairment ofWomen Total
(11.34) 66.21 (14.07) 67.78 (13.05)
.3–3.2%) 12 (4.3–2.4%) 28 (5.6%)
81.4% 35.8%) 182 (65–36.4%) 361 (72.2%)
–1.2%) 12 (4.3–2.4%) 18 (3.6%)
.6–3.8%) 74 (26.4–14.8%) 93 (18.6%)
57.7–25.4%) 207 (73.9–41.4%) 334 (66%)
0.9–13.6%) 53 (18.9–10.6%) 121 (24.2%)
1.4–5%) 20 (7.1–4%) 45 (9%)
68.6–30.2%) 110 (39.3–22%) 261 (52.5%)
4.5–6.4%) 39 (13.9–7.8%) 71 (14.2%)
–0.4%) 104 (37.1–20.8%) 106 (21.2%)
5.9–7%) 27 (9.7–5.4%_ 72 (12.4%)
Table 2 Chronic illnesses and co-morbidities.
Disease Men Women Total
Arterial hypertension 154 (70%) 160 (57.1%) 304 (60.8%)
Dyslipidemia 91 (41.3%) 140 (50%) 231 (46.2%)
Diabetes mellitus 56 (25.4%) 46 (16.4%) 110 (22%)
Coronary heart disease 45 (20.4%) 30 (10.71%) 75 (15%)
Heart failure 17 (7.7%) 25 (10.92) 42 (8.4%)
Chronic arthritis 31 (14%) 78 (27.8%) 109 (21.8%)
Chronic obstructive pulmonary disease 18 (8.18%) 16 (5.71%) 34 (6.8%)
Anti-depressive medication 17 (7.27%) 62 (22.1%) 79 (15.9%)
Other problemsa 144 (65.5%) 149 (50.9%) 293 (58.6%)
a Such as: renal failure, prostate hypertrophy, thyroid dysfunction, various malignancies, Parkinsons disease, stroke, vertigo,
etc.
Table 3 All ages: SDS-Zung, MCS and PCS scores (adjusted for sex and age).
Mean ± 2se (95% CI) Men (n = 220) Women (n = 280) p
SDS Zung 45.80 ± 1.45 42.71 ± 1.45 48.22 ± 1.4 0.000
MCS12 48.29 ± 0.945 50.70 ± 1.29 46.369 ± 1.31 0.000
PCS12 42.84 ± 0.94 43.70 ± 1.40 42.16 ± 1.26 0.068
Age 41–90
SDS Zung 45.70 ± 1.06 42.78 ± 1.45 48.09 ± 1.4 0.000
MCS12 48.35 ± 0.9 50.72 ± 1.3 46.41 ± 1.3 0.000
PCS12 42.77 ± 0.88 43.62 ± 1.4 42.07 ± 1.2 0.060
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(8 participants) of the study population had severe
depressive symptomatology and impairment. These
scores of the above subgroups show statistically
significant differences (p < 0.05) when compared
with the general study population, after stratified
analysis for age, sex, chronic illnesses and other
demographic data that may have led to depressive
symptomatology as described above and in Table 4.
Moreover, this 22.2% of the study population was
under no psychiatric evaluation or treatment of
any kind for depression.
4. Discussion
This cross-sectional study intended to investigate
the presence of depressive symptomatology and
the impairment of quality of life in a primary care
setting. Self-evaluation scales were implemented
that have been used and validated in various stud-
ies [11,12] and settings [9,10,13–18]. Analysis of
demographic data indicated statistically significant
differences (p < 005) between men and women, a
finding concordant with the literature [19–22].
The female predominance in the incidence of
depression is well documented worldwide and this
study serves to show the global burden of a disease
that affects twice as many women than men. Whenstratified analysis was performed, the results were
statistically significant in ages 41–90, which
formed the majority of the study group (Table 3)
and not in younger ages, a finding that may be a
result of the small sample of younger adult
participants, since they do not regularly visit a
health care center for regular appointments. No
association between these findings and the demo-
graphic data (family status, level of education
and profession) of the participants could be identi-
fied; the differences were not statistically
significant.
Association of depressive symptomatology and
impairment of quality of life with chronic illness
is a topic under evaluation in the literature. Cer-
tain chronic illnesses of internal medicine have
been associated positively, such as end-stage renal
failure, Parkinsons disease, cancer and stroke [23–
26]. However, the study group did not have a suffi-
cient number of patients with such diseases to
identify any associations. In more common health
problems in primary care, such as arterial hyper-
tension and dyslipidemia, no associations were
found. Even though there is an association between
diabetes mellitus, depressive symptomatology and
impairment of quality of life in the literature
[26–29], these studies are performed with cohorts
of diabetic patients, many of whom have disabling
Table 4 Co-morbidities, depressive symptomatology and quality of life.
Men Women
Present No disease p Present No disease p
Arterial hypertension 154 66 160 120
SDS-Zung 42.55 ± 1.76 43.10 ± 2.48 0.564 48.68 ± 1.94 47.62 ± 2.066 0.493
MCS12 51.15 ± 1.45 49.83 ± 2.36 0.396 47.17 ± 1.64 45.28 ± 2.12 0.245
PCS12 43.29 ± 1.72 44.65 ± 2.39 0.519 40.40 ± 1.56 44.51 ± 1.98 0.0006
Dyslipidemia 91 129 140 140
SDS-Zung 43.09 ± 2.36 42.44 ± 1.68 0.606 47.70 ± 2 48.75 ± 2 0.428
MCS12 50.71 ± 2.17 50.78 ± 1.58 0.726 47.13 ± 1.8 45.58 ± 1.88 0.274
PCS12 42.95 ± 2.22 44.23 ± 1.8 0.323 42.77 ± 1.62 41.56 ± 1.9 0.478
Diabetes mellitus 56 164 46 234
SDS-Zung 46.07 ± 3.3 41.57 ± 1.59 0.004 48.00 ± 1.94 48.27 ± 1.59 0.589
MCS12 48.12 ± 2.9 51.65 ± 1.39 0.039 48.22 ± 2.86 45.99 ± 1.46 0.225
PCS12 41.50 ± 2.84 44.44 ± 1.6 0.059 40.49 ± 2.9 42.49 ± 1.38 0.821
Coronary heart disease 45 175 46 234
SDS-Zung 47.20 ± 1.98 41.56 ± 1.48 0.005 48.63 ± 2.86 48.18 ± 1.52 0.686
MCS12 49.01 ± 3.62 51.20 ± 1.32 0.514 47.79 ± 3.16 46.18 ± 1.42 0.990
PCS12 38.38 ± 3.21 45.06 ± 1.5 0.000 37.04 ± 2.92 42.78 ± 1.34 0.077
Congestive heart failure 17 223 25 255
SDS-Zung 48.29 ± 7.2 42.25 ± 1.4 0.180 49.52 ± 5.06 48.10 ± 1.46 0.686
MCS12 46.77 ± 6 51.09 ± 1.3 0.207 46.34 ± 4.44 46.36 ± 1.36 0.990
PCS12 37.71 ± 5.8 44.20 ± 1.42 0.028 38.92 ± 3.79 42.48 ± 1.32 0.077
Chronic arthritis 31 189 78 202
SDS-Zung 48.77 ± 4.48 41.72 ± 1.46 0.001 53.32 ± 2.74 46.26 ± 1.56 0.000008
MCS12 46.90 ± 4.32 51.38 ± 1.3 0.086 43.22 ± 2.44 47.57 ± 1.52 0.001
PCS12 36.68 ± 3.72 44.85 ± 1.42 0.00008 38.83 ± 2.24 43.45 ± 1.48 0.0003
COPD 18 202 16 264
SDS-Zung 49.00 ± 6.54 42.15 ± 1.44 0.013 53.18 ± 6.5 47.92 ± 1.44 0.099
MCS12 46.57 ± 5.14 51.13 ± 1.32 0.077 46.87 ± 5.8 46.32 ± 1.34 0.699
PCS12 37.61 ± 5.6 44.24 ± 1.42 0.022 36.57 ± 3.94 42.50 ± 1.3 0.013
Antidepressive medication 17 203 62 218
SDS-Zung 54.52 ± 6.76 41.72 ± 1.38 0.000138 55.70 ± 3.8 46.10 ± 1.32 0.000004
MCS12 40.25 ± 4.78 51.63 ± 1.26 0.000035 39.81 ± 3.12 48.22 ± 1.32 0.000001
PCS12 32.54 ± 5.1 44.63 ± 1.38 0.000045 39.33 ± 2.94 42.97 ± 1.36 0.019790
All correlations adjusted for age data are mean ± 2se (95% CI).
Table 5 Participants with SDS-Zung scores 50–59.
Men n = 22 Women n = 58 Total n = 80
Age (mean ± St. dev (95%CI)) 65.59 ± 4.1 64.32 ± 3.7 64.67 ± 2.99
Diabetes mellitus 6/22 13/58 19/80
Coronary heart disease 4/22 6/58 10/80
Heart failure – 6/58 6/80
Chronic arthritis 3/22 18/58 21/80
Chronic obstructive pulmonary disease 3/22 6/58 9/80
SDS-Zung (mean ± 2se (95% CI)) 53.13 ± 1.14 53.12 ± 0.6 53.12 ± 0.6
MCS12 (mean ± 2se (95% CI)) 45.64 ± 4 43.82 ± 2.2 44.32 ± 1.9
PCS12 (mean ± 2se (95% CI)) 39.64 ± 4 38.98 ± 1.32 39.16 ± 2.2
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foot, problems that this study was not designed
to evaluate and identify.
These results do not associate depressive symp-
tomatology and impairment of quality of life withcoronary heart disease (CHD) or heart failure. In
a review article, Khawaja et al. [30] claim that
CHD is a risk factor for depression and vice versa.
The study group consisted of patients with CHD
and heart failure of different severities, and this
Table 6 Participants with SDS-Zung scores 60–69.
Men n = 8 Women n = 15 Total n = 23
Age (mean ± St. dev (95%CI)) 77.74 ± 4.7 68.73 ± 6.82 71.73 ± 5.56
Diabetes mellitus 5/8 2/15 7/23
Coronary heart disease 3/8 3/15 6/23
Heart failure 1/8 1/15 2/23
Chronic arthritis 4/8 6/15 10/23
Chronic obstructive pulmonary disease – – –
SDS-Zung (mean ± 2se (95% CI)) 62.75 ± 2.02 64.40 ± 1.74 63.82 ± 1.34
MCS12 (mean ± 2se (95% CI)) 36.41 ± 6.84 37.29 ± 4.46 36.99 ± 1.88
PCS12 (mean ± 2se (95% CI)) 33.14 ± 8.06 35.74 ± 6.74 34.83 ± 5.12
250 P. Andriopoulos et al.study was not designed to identify such associa-
tions if they existed. In a meta-analysis of depres-
sion and heart failure, Rutledge et al. [31] found
that at least one out of five patients with heart fail-
ure had depression. Statistically significant differ-
ences were found in patients with chronic
arthritis and COPD. Patients with arthritis have
impairment of quality of life since the course of
such a degenerative disease leads to a physical
and mental burden that may also result in depres-
sion [32–34]. The correlation between COPD
depression and impairment of quality of life is well
described in the literature [35–39]. Severity of
COPD is a major risk factor for depression and phys-
ical impairment in patients who eventually have
major limitations in everyday life. 79 participants
of this study were taking anti-depressive medica-
tion, but they still had statistically significant dif-
ferences in depressive symptomatology and
impairment of quality of life. These findings serve
to show that depression is a complex disease and
medication alone may not be enough to offer re-
lief; however, this study was not designed to inves-
tigate the treatment of such patients and no safe
conclusions can be drawn from these results, even
more so when such issues are still open in the liter-
ature [40,41].
One of the most interesting findings of the pres-
ent study was the identification of depressive
symptomatology and impairment of quality of life
in 163 participants (22.2% of the study population).
Of them, 111 had no awareness of their symptoms,
or of the impaired quality of life, and were not tak-
ing any anti-depressive medication. They had SDS-
Zung scores of 50 and higher: 72% had mild and
20% moderate symptomatology and concordant
impairment of quality of health. This percentage
may seem too large; however, in studies from pri-
mary care settings the results are similar. Ani
et al. [42] in a sample of 315 patients found
32.5% of the population presented with depressive
symptomatology, and other studies from the Uni-ted States have reported similar results [43,44].
Such results show that depression is heavily un-
der-diagnosed in primary care worldwide, and
there is also a female predominance in undiag-
nosed depression.
Several limitations are present in this study. The
study was performed in a rural area, participants
were mainly middle aged and older, with a lower
level of education. Hence, the results are not
safely applied to the whole population. The study
questionnaires are designed to identify depressive
symptomatology and impairment of quality of life
and do not contain detailed information on medical
history or on the severity and staging of chronic dis-
eases. Finally, heterogeneity of the study popula-
tion led to subgroups that numbers made it
impossible to reach conclusions about correlations.
In conclusion, a cross-sectional study was con-
ducted to identify depressive symptomatology
and impairment of quality of life in primary care
settings of a rural area in Greece. The prevalence
of depression and impaired quality of life that
was found indicates the crucial role of primary care
in diagnosis and treatment of depression, as well as
the need for trained personnel that can undertake
this task and improve the quality of life of such
patients.
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